AZN SERENA-4 Phase III Trial for Etcamah in Breast Cancer Did Not Meet Primary Objective
· The NYC Memo
AstraZeneca PLC disclosed that its SERENA-4 Phase III trial of Etcamah, in combination with palbociclib for upfront first-line advanced ER-positive breast cancer, did not meet its primary objective of statistically significant improvement in progression-free survival. The company noted a numerical improvement was observed in the trial.
This information was reported on September 14, 2026.